Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (8)
Language
- English (8)
Keywords
- 18F-FDG PET/CT (2)
- PET (2)
- fibroblast activation protein (2)
- head and neck cancer (2)
- molecular imaging (2)
- multiple myeloma (2)
- relapse (2)
- 11C-Methionine PET/CT (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
Institute
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (7)
- Klinik und Poliklinik für Nuklearmedizin (7)
- Comprehensive Cancer Center Mainfranken (3)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (3)
- Medizinische Klinik und Poliklinik II (3)
- Pathologisches Institut (3)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (2)
- Urologische Klinik und Poliklinik (1)
Utilizing 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT), we performed this pilot study to evaluate the link between cytogenetic/genomic markers and imaging patterns in relapsed/refractory (RR) multiple myeloma (MM). We retrospectively analyzed data of 24 patients with RRMM who were treated at our institution between November 2018 and February 2020. At the last relapse/progression, patients had been treated with a median of three (range 1–10) lines of therapy. Six (25%) patients showed FDG avid extramedullary disease without adjacency to bone. We observed significantly higher maximum standardized uptake values (SUV\(_{max}\)) in patients harboring del(17p) compared with those without del(17p) (p = 0.025). Moreover, a high SUV\(_{max}\) of >15 indicated significantly shortened progression-free survival (PFS) (p = 0.01) and overall survival (OS) (p = 0.0002). One female patient exhibited biallelic TP53 alteration, i.e., deletion and mutation, in whom an extremely high SUV\(_{max}\) of 37.88 was observed. In summary, this pilot study suggested a link between del(17p)/TP53 alteration and high SUV\(_{max}\) on 18F-FDG PET/CT in RRMM patients. Further investigations are highly warranted at this point.